Patent classifications
C12N2710/10351
Production of viral vectors
The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.
Viral vector production system
The present invention relates to a nucleic acid sequence comprising a binding site operably linked to a nucleotide of interest, wherein the binding site is capable of interacting with an RNA-binding protein such that translation of the nucleotide of interest is repressed in a viral vector production cell.
IMMUNOGENIC COMPOSITIONS AND USES THEREOF
Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.
COMPOSITIONS AND METHODS FOR ENHANCING ONCOLYTIC VIRUS EFFICACY
Provided are compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the cytotoxicity of virus to cells. Other uses, compositions and methods of using same are also provided.
COMPOSITIONS AND KITS FOR PURIFICATION OF VIRAL PARTICLES FROM HOST CELLS
The present disclosure provides methods for extracting viral particles from a sample comprising cells enclosing the viral particles. Also provided are kits that includes two or more items selected from a cell suspension solution, a cell lysis solution, a first fractionation solution, a second fractionation solution, a pellet suspension solution, a solid phase chromatography column, and a viral concentration set such as centrifugal filters.
Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses
Provided herein are fumaric and maleic acid-containing compounds, compositions comprising the same and methods for using such compounds to enhance production, growth, spread or titer of interferon-sensitive viruses in cells, particularly cancer and tumor cells. Also provided are methods of treating tumors or cancers in a subject by administering the compounds and compositions.
COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION, GROWTH, SPREAD, OR ONCOLYTIC AND IMMUNOTHERAPEUTIC EFFICACY OF INTERFERON-SENSITIVE VIRUSES
Provided herein are fumaric-containing compounds, compositions comprising the same and methods for using such compounds for increasing the capacity of an interferon-sensitive virus to infect, transduce, grow or replicate in a cell or spread within one or more tissues. Also provided are methods for increasing the capacity of an interferon-sensitive virus to produce a virus-encoded transgene from a cell, by administering the compounds and compositions.
ADENOVIRAL SEROTYPE 35 HELPER VECTORS
The present disclosure provides, among other things, Ad35 helper genomes and vectors useful in gene therapy, e.g., for production of helper-dependent Ad35 donor vectors. Helper genomes of the present disclosure include a conditionally defective packaging sequence.
Analytical ultracentrifugation for characterization of recombinant viral particles
Provided herein are methods to characterize preparations of recombinant viral particles using analytical ultracentrifugation. Recombinant viral particles include recombinant adeno-associated viral particles, recombinant adenoviral particles, recombinant lentiviral particles and recombinant herpes simplex virus particles. Variant species of recombinant viral particles including empty capsids and recombinant viral particles with variant genomes (truncated genomes, aggregates, recombinants) can be identified and quantitated. The methods can be used to characterize preparations of recombinant viral particles regardless of the sequence of the recombinant viral genome or the serotype of the recombinant viral capsid.
IMMUNOGENIC COMPOSITIONS AND USES THEREOF
Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.